{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:19:29Z","timestamp":1789676369005,"version":"4.0.1"},"reference-count":29,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["IJMS"],"abstract":"<jats:p>Genetic abnormalities of the fibroblast growth factor receptor 2 (FGFR2) gene, including amplification, fusions, and mutations, have been reported in various solid tumors. While molecular targeted therapies against FGFR2 fusion have been proved to be useful in cholangiocarcinoma, the therapeutic significance of FGFR2 inhibitors remains unclear in other various solid cancers. Genomic and clinical information from solid tumor cancer gene panel testing cases is consolidated in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database in Japan. This study aimed to utilize the C-CAT database to clarify the clinical\u2013pathological significance of FGFR2 abnormalities. A total of 101,231 patients with solid cancer have been registered in the C-CAT database between June 2019 and June 2025. Of the 101,231 cases, 1312 cases with FGFR2 gene abnormalities were analyzed. FGFR2 alterations included amplification in 515 cases, fusion in 280 cases, and mutations in 568 cases. They were detected most frequently in the biliary tract (271 cases), esophagus\/stomach (231 cases), and breast (211 cases). Amplification was frequent in the esophagus\/stomach (205 cases) and breast (105 cases). Mutations were frequent in the uterus (111 cases), breast (89 cases), and biliary tract (86 cases). Among 515 FGFR2 alteration cases, FGFR2 inhibitors were administered in 85 cases. Of the 85 cases, disease control was achieved in 49 cases, 44 cases of which were biliary tract cancer. FGFR2 might be a promising therapeutic target not only for cholangiocarcinoma with fusion but also for esophagus\/stomach cancer and breast cancer with FGFR2 alterations.<\/jats:p>","DOI":"10.3390\/ijms262110777","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:09:47Z","timestamp":1762358987000},"page":"10777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities"],"prefix":"10.3390","volume":"26","author":[{"given":"Hinano","family":"Nishikubo","sequence":"first","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongheng","family":"Ma","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sano","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Imanishi","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8034-7242","authenticated-orcid":false,"given":"Canfeng","family":"Fan","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurie","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Yamamori","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women\u2019s University, Nishinomiya 663-8179, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-7228","authenticated-orcid":false,"given":"Masakazu","family":"Yashiro","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"},{"name":"Cancer Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1111\/cas.14654","article-title":"Circulating Tumor Cells with FGFR2 Expression Might Be Useful to Identify Patients with Existing FGFR2-overexpressing Tumor","volume":"111","author":"Kuroda","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1021\/acsmedchemlett.3c00006","article-title":"Discovery of Futibatinib: The First Covalent FGFR Kinase Inhibitor in Clinical Use","volume":"14","author":"Ito","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib Is a Novel Irreversible FGFR 1\u20134 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cas.16354","article-title":"Tasurgratinib in Patients with Cholangiocarcinoma or Gastric Cancer: Expansion Part of the First-in-human Phase I Study","volume":"116","author":"Morizane","year":"2025","journal-title":"Cancer Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1007\/s10147-024-02521-3","article-title":"New Therapeutic Target Molecules for Gastric and Gastroesophageal Junction Cancer","volume":"29","author":"Kawakami","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/CCO.0000000000001047","article-title":"State-of-the-Art and Trends in Fibroblast Growth Factor Receptor-Directed Therapies in Gastro-Intestinal Malignancies","volume":"36","author":"Hanssens","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast Growth Factor Receptors in Cancer: Genetic Alterations, Diagnostics, Therapeutic Targets and Mechanisms of Resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_11","first-page":"8848","article-title":"Keratinocyte Growth Factor Produced by Gastric Fibroblasts Specifically Stimulates Proliferation of Cancer Cells from Scirrhous Gastric Carcinoma","volume":"63","author":"Nakazawa","year":"2003","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1053\/j.gastro.2006.08.030","article-title":"A Novel Molecular Targeting Compound as K-SamII\/FGF-R2 Phosphorylation Inhibitor, Ki23057, for Scirrhous Gastric Cancer","volume":"131","author":"Nakamura","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/ijc.24763","article-title":"Synergistic Antitumor Effects of FGFR2 Inhibitor with 5-Fluorouracil on Scirrhous Gastric Carcinoma","volume":"126","author":"Yashiro","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1158\/1078-0432.CCR-10-0531","article-title":"Monoclonal Antibodies to Fibroblast Growth Factor Receptor 2 Effectively Inhibit Growth of Gastric Tumor Xenografts","volume":"16","author":"Zhao","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_15","first-page":"1511","article-title":"Diffuse-Type Gastric Cancer Cells Switch Their Driver Pathways from FGFR2 Signaling to SDF1\/CXCR4 Axis in Hypoxic Tumor Microenvironments","volume":"36","author":"Kinoshita","year":"2015","journal-title":"Carcinogenesis"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yashiro, M., Kuroda, K., Masuda, G., Okuno, T., Miki, Y., Yamamoto, Y., Sera, T., Sugimoto, A., Kushiyama, S., and Nishimura, S. (2021). Clinical Difference between Fibroblast Growth Factor Receptor 2 Subclass, Type IIIb and Type IIIc, in Gastric Cancer. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-84107-x"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","article-title":"C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan","volume":"12","author":"Kohno","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/cas.14754","article-title":"Establishment and Implementation of Cancer Genomic Medicine in Japan","volume":"112","author":"Mukai","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nishikubo, H., Kawabata, K., Kanei, S., Aoyama, R., Ma, D., Sano, T., Imanishi, D., Sakuma, T., Maruo, K., and Fan, C. (2025). Multi-Cancer Genome Profiling for Neurotrophic Tropomyosin Receptor Kinase (NTRK) Fusion Genes: Analysis of Profiling Database of 88,688 Tumors. Cancers, 17.","DOI":"10.3390\/cancers17132250"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2017.02.031","article-title":"FGFR2 Mutations Are Associated with Poor Outcomes in Endometrioid Endometrial Cancer: An NRG Oncology\/Gynecologic Oncology Group Study","volume":"145","author":"Jeske","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent Activating FGFR2 Mutations in Endometrial Carcinomas Parallel Germline Mutations Associated with Craniosynostosis and Skeletal Dysplasia Syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9714570","DOI":"10.1155\/2022\/9714570","article-title":"Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing","volume":"2022","author":"Hyung","year":"2022","journal-title":"J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e2400027","DOI":"10.1200\/OA.24.00027","article-title":"Age and Sex Affects the Frequency and Mutation Type of FGFR2 Alterations in Cholangiocarcinoma","volume":"1","author":"Hu","year":"2024","journal-title":"JCO Oncol. Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MOG.0000000000000171","article-title":"Fibroblast Growth Factor Receptor 2 Fusions as a Target for Treating Cholangiocarcinoma","volume":"31","author":"Borad","year":"2015","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-Sensitive FGFR2 Mutations in Endometrial Carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/cas.13969","article-title":"Feasibility and Utility of a Panel Testing for 114 Cancer-Associated Genes in a Clinical Setting: A Hospital-Based Study","volume":"110","author":"Sunami","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yatabe, Y., Sunami, K., Goto, K., Nishio, K., Aragane, N., Ikeda, S., Inoue, A., Kinoshita, I., Kimura, H., and Sakamoto, T. (2020). Multiplex Gene-Panel Testing for Lung Cancer Patients. Pathology International, Blackwell Publishing.","DOI":"10.1111\/pin.13023"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., and Clark, T. (2020). Clinical and Analytical Validation of Foundation One Liquid CDx, a Novel 324-Gene CfDNA-Based Comprehensive Genomic Profiling Assay for Cancers of Solid Tumor Origin. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237802"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/cas.70071","article-title":"Real-World Data Analysis of Genomic Alterations Detected by a Dual DNA\u2013RNA Comprehensive Genomic Profiling Test","volume":"116","author":"Watanabe","year":"2025","journal-title":"Cancer Sci."}],"updated-by":[{"DOI":"10.3390\/ijms27020665","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000}}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T09:31:18Z","timestamp":1767951078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/21\/10777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":29,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["ijms262110777"],"URL":"https:\/\/doi.org\/10.3390\/ijms262110777","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}